ESR1 and breast carcinoma: Among HER2-positive breast cancers, approximately 50% are also ER-positive, leading to the division of patients into two main subgroups: ER-negative/HER2-positive and ER-positive/HER2-positive, each with distinct growth patterns and responses to treatment [3].